Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 18, 2023 - Issue
Submit an article Journal homepage
188
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England

Gema Requena1 GSK, R&D Global Medical, Brentford, Middlesex, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1889-6656View further author information
ORCID Icon,
Alexandrosz Czira1 GSK, R&D Global Medical, Brentford, Middlesex, UKORCID Iconhttps://orcid.org/0000-0002-3395-6186View further author information
ORCID Icon,
Victoria Banks2 Real-World Evidence, Adelphi Real World, Bollington, Cheshire, UKORCID Iconhttps://orcid.org/0000-0002-0087-7641View further author information
ORCID Icon,
Robert Wood2 Real-World Evidence, Adelphi Real World, Bollington, Cheshire, UKORCID Iconhttps://orcid.org/0000-0002-6977-435XView further author information
ORCID Icon,
Theo Tritton2 Real-World Evidence, Adelphi Real World, Bollington, Cheshire, UKView further author information
,
Catherine Castillo2 Real-World Evidence, Adelphi Real World, Bollington, Cheshire, UKORCID Iconhttps://orcid.org/0000-0002-7204-6169View further author information
ORCID Icon,
Jie Yeap2 Real-World Evidence, Adelphi Real World, Bollington, Cheshire, UKView further author information
,
Rosie Wild2 Real-World Evidence, Adelphi Real World, Bollington, Cheshire, UKORCID Iconhttps://orcid.org/0000-0002-9963-6441View further author information
ORCID Icon,
Chris Compton1 GSK, R&D Global Medical, Brentford, Middlesex, UKORCID Iconhttps://orcid.org/0000-0002-7564-5343View further author information
ORCID Icon,
Kieran J Rothnie1 GSK, R&D Global Medical, Brentford, Middlesex, UKORCID Iconhttps://orcid.org/0000-0003-4279-1624View further author information
ORCID Icon,
Felix JF Herth3 Department of Pneumology and Critical Care Medicine, Thoraxklinik, University of Heidelberg and Translational Lung Research Center Heidelberg, Heidelberg, GermanyORCID Iconhttps://orcid.org/0000-0002-7638-2506View further author information
ORCID Icon,
Jennifer K Quint4 National Heart and Lung Institute, Imperial College London, London, UKORCID Iconhttps://orcid.org/0000-0003-0149-4869View further author information
ORCID Icon &
Afisi S Ismaila5 Value Evidence and Outcomes, GSK, Collegeville, PA, USA;6 Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, CanadaORCID Iconhttps://orcid.org/0000-0002-2876-8308View further author information
ORCID Icon show all
Pages 2039-2054 | Received 09 Mar 2023, Accepted 31 Aug 2023, Published online: 15 Sep 2023

References

  • Akwe J, Fair N, Fongeh T. Overview of epidemiology, pathophysiology, diagnosis and staging with 2020 Updates. Med Res Arch. 2020;8(2). doi:10.18103/mra.v8i2.2046
  • Chronic obstructive pulmonary disease (COPD) statistics: British Lung Foundation. Availablr from: https://statistics.blf.org.uk/copd. Accessed September 1, 2023.
  • The 2nd Atlas of variation in risk factors and healthcare for respiratory disease in England. Availablr from: https://fingertips.phe.org.uk/documents/Introduction.pdf. Accessed September 1, 2023.
  • Shah CH, Onukwugha E, Zafari Z, Villalonga-Olives E, Park JE, Slejko JF. Economic burden of comorbidities among COPD Patients hospitalized for acute exacerbations: an analysis of a commercially insured population. Expert Rev Pharmacoecon Outcomes Res. 2022;22(4):683–690. doi:10.1080/14737167.2021.1981291
  • Global Initiative for Chronic Obstructive Pulmonary Disease. Global strategy for prevention, diagnosis and management of COPD; 2021. Availablr from: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf. Accessed September 1, 2023.
  • National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing; 2018. Availablr from: https://www.nice.org.uk/guidance/ng114. Accessed September 1, 2023.
  • Plate T, Friedrich FW, Beier J. Effectiveness and tolerability of LABA/LAMA fixed-dose combinations Aclidinium/formoterol, glycopyrronium/indacaterol and umeclidinium/vilanterol in the treatment of COPD in daily practice–results of the non-interventional DETECT study. Int J Chron Obstruct Pulmon Dis. 2020;15:1335. doi:10.2147/COPD.S252354
  • Chapman KR, Bergeron C, Bhutani M, et al. Do we know the minimal clinically important difference (MCID) for COPD exacerbations? J Chronic Obstructive Pulmonary Dis. 2013;10(2):243–249. doi:10.3109/15412555.2012.733463
  • Rothnie KJ, Müllerová H, Thomas SL, et al. Recording of hospitalizations for acute exacerbations of COPD in UK electronic health care records. Clin Epidemiol. 2016;8:771. doi:10.2147/CLEP.S117867
  • Rothnie KJ, Müllerová H, Hurst JR, et al. Validation of the recording of acute exacerbations of COPD in UK primary care electronic healthcare records. PLoS One. 2016;11(3):e0151357. doi:10.1371/journal.pone.0151357
  • Austin PC. Goodness‐of‐fit diagnostics for the propensity score model when estimating treatment effects using covariate adjustment with the propensity score. Pharmacoepidemiol Drug Saf. 2008;17(12):1202–1217. doi:10.1002/pds.1673
  • Lee HW, Park J, Jang EJ, Lee C-H. Comparisons of exacerbations and mortality among LAMA/LABA combinations in stable chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis. Respir Res. 2020;21(1):1–15. doi:10.1186/s12931-020-01540-8
  • Ismaila AS, Haeussler K, Czira A, et al. Comparative efficacy of umeclidinium/vilanterol versus other bronchodilators for the treatment of chronic obstructive pulmonary disease: a network meta-analysis. Adv Ther. 2022;1–51.
  • Hsieh M-J, Chen N-H, Cheng S-L, et al. Comparing Clinical Outcomes of Tiotropium/Olodaterol, Umeclidinium/Vilanterol, and Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Patients with Chronic Obstructive Pulmonary Disease in Taiwan: a Multicenter Cohort Study. Int J Chron Obstruct Pulmon Dis. 2022;17:967. doi:10.2147/COPD.S353799
  • Requena G, Banks V, Czira A, et al. Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist Dual Therapy in a Primary Care Setting in England. Int J Chron Obstruct Pulmon Dis. 2022;17:1781. doi:10.2147/COPD.S365480
  • Requena G, Wolf A, Williams R, et al. Feasibility of using Clinical Practice Research Datalink data to identify patients with chronic obstructive pulmonary disease to enrol into real‐world trials. Pharmacoepidemiol Drug Saf. 2021;30(4):472–481. doi:10.1002/pds.5188
  • Wolf A, Dedman D, Campbell J, et al. Data resource profile: clinical practice research Datalink (CPRD) aurum. Int J Epidemiol. 2019;48(6):1740–1740g. doi:10.1093/ije/dyz034
  • Quint JK, Müllerova H, DiSantostefano RL, et al. Validation of chronic obstructive pulmonary disease recording in the Clinical Practice Research Datalink (CPRD-GOLD). BMJ open. 2014;4(7):e005540. doi:10.1136/bmjopen-2014-005540

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.